ArticleProceedings of the National Academy of Sciences of the United States of America1990
Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 72 citations in OpenAlex.
- Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients.British journal of cancer · 1996Trial
- ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.Peptides · 2015Article
- Investigating contactless high frequency ultrasound microbeam stimulation for determination of invasion potential of breast cancer cells.Biotechnology and bioengineering · 2013Article
- Characterisation of AmphiAmR11, an amphioxus (Branchiostoma floridae) D2-dopamine-like G protein-coupled receptor.PloS one · 2013Article
- Immunohistochemical study on the distribution of neuronal nitric oxide synthase-immunoreactive neurons in the spinal cord of aged rat.Journal of molecular histology · 2005Article
- Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Article
- Bradykinin binding sites in healthy and carcinomatous human lung.British journal of pharmacology · 1994Article
- Neurohypophyseal peptides as regulators of growth and development. A review.Journal of molecular neuroscience : MN · 1993Review
- Characterization of ligand binding and processing by gastrin-releasing peptide receptors in a small-cell lung cancer cell line.The Biochemical journal · 1992Article
- Review
- Activation of muscarinic acetylcholine receptors inhibits cell cycle progression of small cell lung carcinoma.Cell regulation · 1991Article
- Neuropeptide growth factors and cancer.British journal of cancer · 1991Review
- The spatial distribution of exposed nuclear DNA in normal, cancer, and reverse-transformed cells.Proceedings of the National Academy of Sciences of the United States of America · 1990Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Calcium ion flux following the administration of a series of neuropeptides, N6,O2'-dibutyryladenosine 3',5'-cyclic monophosphate, and serum was monitored by flow cytometry in selected lung and breast cancer cell lines and Chinese hamster ovary cell line CHO-K1. Calcium ion flux was monitored in individual cells by flow cytometry using the indicator indo-1 AM. Five groups of neuropeptides produced calcium flux changes in lung cancer cell lines and CHO-K1 cells but not in breast cancer cells. The peak increase in free calcium was reached within 10 sec of peptide administration and declined to resting levels in 70-120 sec. When two or more members of the same group were administered simultaneously, calcium flux changes were identical to that produced by each single peptide. When two or more members of different groups were administered simultaneously, an increased calcium release occurred. When identical peptides or peptides from the same group were administered sequentially after the return of calcium concentrations to resting values, no calcium flux resulted from the second peptide. When peptides from different active groups were administered sequentially, a new calcium flux occurred after each peptide. These data are interpreted to mean that members of each active group of peptides trigger a different calcium flux pathway. Thus, many such pathways and different metabolic states exist within the cell. Elucidation of calcium flux pathways in normal and cancer cells may lead to greater understanding of the nature of the malignant defect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.